Sanofi Pasteur and MSD end joint vaccines business in

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
178
Sanofi Pasteur and MSD end joint vaccines business in Europe

Sanofi Pasteur and MSD end joint vaccines business in Europe

Paris, France - January 2, 2017 - Sanofi and its vaccines global business unit Sanofi Pasteur confirmed today the end of their vaccine joint-venture with MSD (known as Merck & Co. Inc., in the United States and Canada), Sanofi Pasteur MSD (SPMSD). Sanofi Pasteur and MSD will separately pursue their own vaccine strategies in Europe, integrating their respective European vaccines business into their operations. The change in operations took effect January 1, 2017.

Since its announcement in March 2016, the project has been managed in an open dialogue with the SPMSD employees, unions and relevant external stakeholders, in compliance with the applicable rules and regulations. During the transitional period following the announcement of the ending of the joint-venture, SPMSD and Sanofi and Merck, its shareholders, have been focused on a smooth and orderly transition while achieving their public healthcare goals and upholding their commitments to their employees, customers and business partners.

Each company will be able to define its own vaccines strategy to benefit public health and create value for patients, healthcare professionals, and payers. In November 2015, as part of its strategic roadmap 2020, Sanofi announced that it would reshape its portfolio, namely through sustained leadership in vaccines.

About Sanofi Sanofi, a global healthcare leader, discovers, develops and distributes therapeutic solutions focused on patients' needs. Sanofi is organized into five global business units: Diabetes and Cardiovascular, General Medicines and Emerging Markets, Sanofi Genzyme, Sanofi Pasteur and Consumer Healthcare. Sanofi is listed in Paris (EURONEXT: SAN ) and in New York (NYSE: SNY ).

Sanofi Pasteur, the vaccines division of Sanofi, provides more than 1 billion doses of vaccine each year, making it possible to immunize more than 500 million people across the globe. A world leader in the vaccine industry, Sanofi Pasteur produces a portfolio of high quality vaccines that matches its areas of expertise and meets public-health demand. The company's heritage, to create vaccines that protect life, dates back more than a century. Sanofi Pasteur is the largest company entirely dedicated to vaccines. Every day, the company invests more than EUR 1 million in research and development. For more information, please visit: www.sanofipasteur.com or www.sanofipasteur.us

Forward Looking Statements of Sanofi This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include projections and estimates and their underlying assumptions, statements regarding plans, objectives, intentions and expectations with respect to future financial results, events, operations, services, product development and potential, and statements regarding future performance. Forward-looking statements are generally identified by the words "expects", "anticipates", "believes", "intends", "estimates", "plans" and similar expressions. Although Sanofi's management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Sanofi, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include among other things, the uncertainties inherent in research and development, future clinical data and analysis, including post marketing, decisions by regulatory authorities, such as the FDA or the EMA, regarding whether and when to approve any drug, device or biological application that may be filed for any such product candidates as well as their decisions regarding labelling and other matters that could affect the availability or commercial potential of such product candidates, the absence of guarantee that the product candidates if approved will be commercially successful, the future approval and commercial success of therapeutic alternatives, the Group's ability to benefit from external growth opportunities, trends in exchange rates and prevailing interest rates, the impact of cost containment initiatives and subsequent changes thereto, the average number of shares outstanding as well as those discussed or identified in the public filings with the SEC and the AMF made by Sanofi, including those listed under "Risk Factors" and "Cautionary Statement Regarding Forward-Looking Statements" in Sanofi's annual report on Form 20-F for the year ended December 31, 2015. Other than as required by applicable law, Sanofi does not undertake any obligation to update or revise any forward-looking information or statements.  

Contacts:

Media Relations Laurence Bollack Tel. : +33 (0)1 53 77 46 46 mr@sanofi.com Investor Relations George Grofik Tel.: +33 (0)1 53 77 45 45 ir@sanofi.com
Attachments:

http://www.globenewswire.com/NewsRoom/Attachm...7737ad6e9f

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Better Life Science: Revolutionizing At-Home STI Testing

Updated Category News Views 50

Paving a New Path for STI Testing Accessibility The landscape of STI testing is undergoing a significant shift, and Better Life Science is at the helm with their innovative STD Hero at-home testing service. With a splash in the latest AVN report, they're turning heads in both the clinical world and in mainstream society. This ain't just about checking boxes in health...

Continue Reading
MacKenzie-Childs Grinds Into Spotlight with Oprah's Nod

Updated Category News Views 50

Oprah's Golden Touch: 30 Years Strong Every year, there are a few select spots that brands covet like a hawk on a rabbit hunt. Getting on Oprah’s 'Favorite Things' list is surely one of them. Just like that, the MacKenzie-Childs Electric Salt and Pepper Grinder Set has muscled its way into the 2026 selection. Spare me the bells and whistles; this is like hitting the...

Continue Reading
Hanwha Power Seals Second FSRU Conversion Deal

Updated Category News Views 168

Riding the FSRU Wave with Hanwha Power Alright, we've got Hanwha Power step-dancing onto the LNG stage with its second splash into the FSRU (Floating Storage and Regasification Unit) conversion gig. Partnering up with Energos Infrastructure, these guys are making serious waves in the energy market by transforming what's pretty much a regular ship into a floating gas...

Continue Reading
Pollo AI Unveils York AI: Automating Social Growth

Updated Category News Views 202

York AI Debuts as the New Kid on the Block Amid the hustle and bustle of a tech-savvy Singapore, Pollo AI’s latest offering, York AI, sashays onto the scene with the promise of putting social media growth on cruise control. We're talking about a digital sidekick that seems to know your online persona better than you do. It’s tailored for everyone from the small-time...

Continue Reading
ICCSD in Beijing: AI and Culture's Future Explored

Updated Category News Views 136

AI's Intersection with Culture in the Spotlight Imagine a room full of people hammering out the future of AI and culture—it starts to feel like a melting pot for the mind. That was the scene in Beijing when the ICCSD Advisory Committee congregated on October 26, 2026. With experts pooling from four different countries, there was no shortage of fireworks. They hashed out...

Continue Reading
Flagship's £100M London Move to Ignite AI Ventures

Updated Category News Views 201

London Calling: Flagship's New Venture Flagship Pioneering, the brain behind bustling biotech ventures like Moderna, is planting its flag in London. They're launching Flagship Origination Lab, U.K., their first real gig outside good ol' Cambridge, Massachusetts. They're diving in headfirst, sprinkling a whopping £100 million to brew up AI-native platform companies. And...

Continue Reading
Exploring Why Dead Outlets Stay Dead: Expert Insights

Updated Category News Views 29

The Mystery of Non-Responsive Outlets Ever found an electrical outlet refusing to cooperate when you need it most? Well, I know the frustration all too well. You'd think if the breaker ain't blown, the outlet should work like a charm. But dive into the guts of the story, and you find a series of surprises waiting to trip us up. Common Culprits: Tripped GFCIs and Loose...

Continue Reading
Pony.ai & Toyota Launch 1,000 Gen-7 Robotaxis in China

Updated Category News Views 153

Revving Up the Autonomous Ride Revolution Not every day you see two giants, Pony.ai and Toyota, join forces to shake up the way folks get from A to B. But here we are — they’ve fired up their engines in Guangzhou, unleashing their Gen-7 bZ4X Robotaxis for commercial use. And let me tell you, this is no shot in the dark. With plans to dot about 1,000 of these...

Continue Reading
Life Insurance: Evolving with Your Financial Journey

Updated Category News Views 32

Why Life Insurance Isn't Just a 'Set It and Forget It' Life insurance isn't some one-time deal you lock in and toss aside. Mike Newell, an insurance pro, highlights how life's shifts—whether in income, dependents, or debt—should drive tweaks to your coverage. As your life story unfolds, so too should the backbone of your financial security. Early Adulthood: Setting...

Continue Reading
Ranger and Smith Unveil Tea-Infused Chocolate Bar

Updated Category News Views 11

Fresh Collaborations in Portland's Culinary Scene Ah, the sweet crossover in Portland's food scene is once again in the spotlight with a new entry that's sure to titillate taste buds. Ranger Chocolate Co. and Steven Smith Teamaker are at it again, rolling out a delectable creation that merges the poetic elegance of tea with the indulgent richness of chocolate. Welcome,...

Continue Reading

Top 5 Most Recently Viewed Articles

Conrad Industries Reports Strong Third Quarter Financial Growth

Updated Category News Views 393

Conrad Industries Announces Third Quarter 2024 Financial Results Conrad Industries, Inc. (OTC Pink: CNRD) recently shared its financial performance for the third quarter ending September 30, 2024. The company reported a net income of $7.5 million, translating to earnings per diluted share of $1.49. This marks a significant turnaround from the third quarter of 2023, which...

Continue Reading
CytoSorbents Webinar Aims to Combat Sepsis and Septic Shock

Updated Category News Views 129

Understanding the Impact of Sepsis and Septic Shock Sepsis and septic shock pose serious threats in critical healthcare settings. Each year, millions of people are affected by these life-threatening conditions. Recognizing the need for innovative solutions, CytoSorbents Corporation has been at the forefront, utilizing its proprietary blood purification technologies to...

Continue Reading
Summa Defence Plc Updates Shareholding Structure Details

Updated Category News Views 271

Overview of Recent Notifications by Summa Defence Plc Summa Defence Plc has made important announcements relating to their shareholding structure and corporate governance, underscoring the dynamic nature of stockholder engagement. These events reflect the ongoing changes in ownership percentages that can significantly impact their operational strategy. Notification of...

Continue Reading
Quantifind's AI Tech Earns High Marks in Compliance

Updated Category News Views 17

Quantifind among the Industry's Top Innovators Well, here's a name to watch: Quantifind. Recognized as a Top 10 technology provider in financial crime and compliance, this Palo Alto-based firm is making waves. Our friends over at Chartis seem to think highly of them, and they don't toss out accolades willy-nilly. So, what's Quantifind doing that's so special? Pioneering...

Continue Reading
Dolby Laboratories Posts Strong Q1 Results with Promising Growth

Updated Category News Views 164

Strong Start for Dolby Laboratories in FY 2026 Dolby Laboratories, Inc. (NYSE: DLB) recently shared its financial results for the first quarter of fiscal 2026, showcasing promising developments despite the challenging market landscape. The company remains optimistic about its position and future growth opportunities. Kevin Yeaman, President and CEO of Dolby, expressed...

Continue Reading